Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

BACKGROUND: To identify possible differences in cardiovascular (CV) risk among different insulin therapies, we performed pre-specified meta-analyses across the clinical program for basal insulin peglispro (BIL), in patients randomized to treatment with BIL or comparator insulin [glargine (IG) or NPH...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoogwerf, Byron J., Lincoff, A. Michael, Rodriguez, Angel, Chen, Lei, Qu, Yongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869328/
https://www.ncbi.nlm.nih.gov/pubmed/27188479
http://dx.doi.org/10.1186/s12933-016-0393-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869328/
https://www.ncbi.nlm.nih.gov/pubmed/27188479
http://dx.doi.org/10.1186/s12933-016-0393-6

Ejemplares similares